Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Accumulated Depreciation (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Accumulated Depreciation for 10 consecutive years, with $29.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 37.03% to $29.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.1 million through Dec 2025, up 37.03% year-over-year, with the annual reading at $29.1 million for FY2025, 37.03% up from the prior year.
  • Accumulated Depreciation hit $29.1 million in Q4 2025 for Rocket Pharmaceuticals, up from $27.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $29.1 million in Q4 2025 to a low of $2.7 million in Q1 2021.
  • Historically, Accumulated Depreciation has averaged $13.7 million across 5 years, with a median of $12.0 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation: soared 200.35% in 2021 and later soared 37.03% in 2025.
  • Year by year, Accumulated Depreciation stood at $5.2 million in 2021, then soared by 74.1% to $9.1 million in 2022, then surged by 54.32% to $14.0 million in 2023, then soared by 51.46% to $21.3 million in 2024, then soared by 37.03% to $29.1 million in 2025.
  • Business Quant data shows Accumulated Depreciation for RCKT at $29.1 million in Q4 2025, $27.4 million in Q3 2025, and $25.7 million in Q2 2025.